Gene Therapy
iwMyeloma Session II: the tumor microenvironment and mechanisms of resistance to targeted therapies
The 16th International Workshop on Multiple Myeloma (iwMyeloma) 2023 took place in Madrid, Spain, and brought together leading clinicians and…
Date: 19th April 2023
Insights into the changing role of chemotherapy in lymphoma
Although several novel agents have been implemented in the treatment of Hodgkin and non-Hodgkin lymphoma (HL; NHL), chemotherapy remains the…
Date: 31st March 2023
Managing and treating toxicities associated with CAR-T therapy: CRS, ICANS & infections
CAR-T cell therapy represents a major breakthrough in the treatment of hematological malignancies, including multiple myeloma, non-Hodgkin lymphoma (NHL), and…
Date: 16th March 2023
The growing role of immunotherapy in the treatment of ALL & moving away from stem cell transplantation
Over the years, the treatment landscape of B-cell acute lymphoblastic leukemia (B-ALL) has transformed with the implementation of novel immunotherapies,…
Date: 10th March 2023
The current status of CAR-T therapy in CLL and challenges in this space
In recent years, novel immunotherapies, including CAR-T cell therapy, have greatly improved treatment options for patients with hematological malignancies. Although CAR-T…
Date: 3rd March 2023
Novel immune therapies in MDS and challenges in this space
Myelodysplastic syndromes (MDS) represent a group of heterogeneous diseases which remain a challenge to treat, and several novel therapies are…
Date: 7th February 2023
NHL highlights at ASH 2022: updates in MCL, the role of transplantation, and novel bispecific antibodies
The 64th American Society of Hematology (ASH) Annual Meeting and Exposition took place on December 10-13, 2022, in New Orleans, LA,…
Date: 2nd February 2023
T-cell lymphoma highlights at ASH 2022: unmet needs, clinical trial updates & future outlooks
The 64th American Society of Hematology (ASH) Annual Meeting and Exposition took place on December 10-13, 2022, in New Orleans, LA,…
Date: 20th January 2023
Myeloma highlights at ASH 2022: improving access to CAR-T therapy & future outlooks
The 64th American Society of Hematology (ASH) Annual Meeting and Exposition took place on December 10-13, 2022, in New Orleans,…
Date: 3rd January 2023
iwNHL Session IV: T-cell therapies for NHL: CAR-T therapies & third-party EBV T-cells
The 19th International Workshop on Non-Hodgkin Lymphoma (iwNHL) 2022 took place in Barcelona, Spain, and brought together leading experts in…
Date: 30th November 2022
iwAL 2022 Session IV: the evolving treatment landscape in ALL and the growing role of immunotherapies
The 4th International Workshop on Acute Leukemias (iwAL) 2022 took place in Nice, France, and brought together leading experts in the…
Date: 22nd November 2022
iwNHL Session III: exploring the optimal management of R/R follicular lymphoma in an expanding treatment landscape
The 19th International Workshop on Non-Hodgkin Lymphoma (iwNHL) 2022 took place in Barcelona, Spain, and brought together leading experts in…
Date: 18th November 2022